...
首页> 外文期刊>Bioorganic and Medicinal Chemistry >New quinoxaline 1,4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1,4-di-N-oxides.
【24h】

New quinoxaline 1,4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1,4-di-N-oxides.

机译:新的喹喔啉1,4-二-N-氧化物。第1部分:来自喹喔啉1,4-二-N-氧化物的缺氧选择性细胞毒素和抗癌药。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Hypoxic cells which are common feature of solid tumors are resistant to both anticancer drugs and radiation therapy. Thus, the identification of drugs with the selective toxicity toward hypoxic cells is an important target in anticancer chemotherapy. Tirapazamine has been shown to be an efficient and selective cytotoxin after bioreductive activation in hypoxic cells which is thought to be due to the presence of the 1,4-di-N-oxide. A new series of quinoxaline 1,4-di-N-oxides and fused quinoxaline di-N-oxides were synthesized and evaluated for hypoxic-cytotoxic activity on EAC cell line. Compound 10a was the most potent cytotoxin IC(50) 0.9 microg/mL, potency 75 microg/mL, and was approximately 15 times more selective cytotoxin (HCR>111) than 3-aminoquinoxaline-2-carbonitrile which has been used as a standard (HCR>7.5). Compounds 4 and 3a,b were more selective than the standard. In addition, antitumor activity against Hepg2 (liver) and U251 (brain) human cell lines was evaluated, compounds 9c and 8a werethe most active against Hepg2 with IC(50) values 1.9 and 2.9 microg/mL, respectively, however, all the tested compounds were nontoxic against U251 cell line.
机译:实体瘤常见的缺氧细胞对抗癌药和放射疗法均具有抗性。因此,鉴定对低氧细胞具有选择性毒性的药物是抗癌化学疗法的重要目标。在低氧细胞中进行生物还原活化后,Tirapazamine已被证明是一种有效的选择性细胞毒素,这被认为是由于1,4-二-N-氧化物的存在。合成了一系列新的喹喔啉1,4-二-N-氧化物和稠合的喹喔啉二-N-氧化物,并评估了其对EAC细胞系的低氧细胞毒活性。化合物10a是最有效的细胞毒素IC(50)0.9微克/毫升,效力为75微克/毫升,是选择性的细胞毒素(HCR> 111)的三倍于已用作标准品的3-氨基喹喔啉-2-甲腈(HCR> 7.5)。化合物4和3a,b比标准品更具选择性。此外,评估了针对Hepg2(肝)和U251(脑)人类细胞系的抗肿瘤活性,化合物9c和8a对Hepg2的活性最高,IC(50)值分别为1.9和2.9 microg / mL,但是,所有测试的这些化合物对U251细胞系无毒。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号